American Century Companies’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.8M | Sell |
150,298
-8,187
| -5% | -$1.09M | 0.01% | 1186 |
|
|
2025
Q4 | $22.5M | Buy |
158,485
+19,572
| +14% | +$2.84M | 0.01% | 1109 |
|
|
2025
Q3 | $19.5M | Sell |
138,913
-52,349
| -27% | -$7.09M | 0.01% | 1161 |
|
|
2025
Q2 | $24M | Buy |
191,262
+80
| +0% | +$9.17K | 0.01% | 1003 |
|
|
2025
Q1 | $21.1M | Buy |
191,182
+98,659
| +107% | +$12.5M | 0.01% | 1014 |
|
|
2024
Q4 | $12.6M | Sell |
92,523
-88,727
| -49% | -$11M | 0.01% | 1246 |
|
|
2024
Q3 | $20.9M | Sell |
181,250
-17,286
| -9% | -$2.37M | 0.01% | 1004 |
|
|
2024
Q2 | $27.3M | Sell |
198,536
-28,483
| -13% | -$3.91M | 0.02% | 815 |
|
|
2024
Q1 | $31.3M | Sell |
227,019
-555,025
| -71% | -$75.8M | 0.02% | 743 |
|
|
2023
Q4 | $103M | Sell |
782,044
-231,700
| -23% | -$26.7M | 0.07% | 302 |
|
|
2023
Q3 | $114M | Sell |
1,013,744
-90,523
| -8% | -$9.53M | 0.09% | 252 |
|
|
2023
Q2 | $104M | Buy |
1,104,267
+242,362
| +28% | +$23.7M | 0.08% | 277 |
|
|
2023
Q1 | $87.2M | Buy |
861,905
+56,405
| +7% | +$5.87M | 0.07% | 301 |
|
|
2022
Q4 | $96.2M | Sell |
805,500
-238,010
| -23% | -$27.9M | 0.08% | 277 |
|
|
2022
Q3 | $111M | Sell |
1,043,510
-69,322
| -6% | -$7.03M | 0.1% | 234 |
|
|
2022
Q2 | $108M | Buy |
1,112,832
+316,984
| +40% | +$29.3M | 0.09% | 250 |
|
|
2022
Q1 | $74.6M | Buy |
795,848
+670,415
| +534% | +$56.8M | 0.05% | 353 |
|
|
2021
Q4 | $10.7M | Buy |
125,433
+6,115
| +5% | +$563K | 0.01% | 856 |
|
|
2021
Q3 | $11.4M | Sell |
119,318
-11,171
| -9% | -$1.06M | 0.01% | 808 |
|
|
2021
Q2 | $12.7M | Sell |
130,489
-15,220
| -10% | -$1.46M | 0.01% | 768 |
|
|
2021
Q1 | $14.2M | Sell |
145,709
-308
| -0.2% | -$32.3K | 0.01% | 710 |
|
|
2020
Q4 | $14M | Sell |
146,017
-56,578
| -28% | -$5.46M | 0.01% | 698 |
|
|
2020
Q3 | $19.5M | Sell |
202,595
-14,094
| -7% | -$1.63M | 0.02% | 541 |
|
|
2020
Q2 | $26.4M | Buy |
216,689
+58,175
| +37% | +$6.43M | 0.03% | 457 |
|
|
2020
Q1 | $13.7M | Sell |
158,514
-74,509
| -32% | -$7.29M | 0.02% | 528 |
|
|
2019
Q4 | $25M | Buy |
233,023
+6,854
| +3% | +$718K | 0.02% | 456 |
|
|
2019
Q3 | $20.4M | Buy |
226,169
+336
| +0.1% | +$31.4K | 0.02% | 489 |
|
|
2019
Q2 | $19.1M | Buy |
225,833
+40,185
| +22% | +$3.3M | 0.02% | 512 |
|
|
2019
Q1 | $16.4M | Buy |
185,648
+37,507
| +25% | +$3.13M | 0.02% | 525 |
|
|
2018
Q4 | $10.6M | Buy |
+148,141
| New | +$14.2M | 0.01% | 597 |
|
|
2018
Q3 | – | Sell |
-566,895
| Closed | -$55.7M | – | 1329 |
|
|
2018
Q2 | $55.7M | Buy |
566,895
+69,701
| +14% | +$6.24M | 0.06% | 337 |
|
|
2018
Q1 | $41.2M | Buy |
497,194
+6,546
| +1% | +$553K | 0.04% | 384 |
|
|
2017
Q4 | $38.1M | Buy |
490,648
+454,500
| +1,257% | +$31M | 0.04% | 421 |
|
|
2017
Q3 | $2.21M | Buy |
36,148
+2,443
| +7% | +$129K | ﹤0.01% | 1015 |
|
|
2017
Q2 | $1.55M | Buy |
33,705
+886
| +3% | +$43K | ﹤0.01% | 1075 |
|
|
2017
Q1 | $1.42M | Sell |
32,819
-277,416
| -89% | -$11.9M | ﹤0.01% | 1094 |
|
|
2016
Q4 | $12M | Sell |
310,235
-570,272
| -65% | -$25.8M | 0.01% | 628 |
|
|
2016
Q3 | $44.6M | Buy |
880,507
+58,980
| +7% | +$2.94M | 0.05% | 378 |
|
|
2016
Q2 | $37.3M | Buy |
821,527
+738,598
| +891% | +$34M | 0.04% | 421 |
|
|
2016
Q1 | $3.28M | Sell |
82,929
-2,478
| -3% | -$98.3K | ﹤0.01% | 914 |
|
|
2015
Q4 | $4.83M | Buy |
85,407
+6,264
| +8% | +$318K | 0.01% | 844 |
|
|
2015
Q3 | $3.15M | Buy |
79,143
+38,079
| +93% | +$1.84M | ﹤0.01% | 953 |
|
|
2015
Q2 | $1.96M | Sell |
41,064
-10,706
| -21% | -$454K | ﹤0.01% | 1031 |
|
|
2015
Q1 | $2.06M | Sell |
51,770
-9,487
| -15% | -$339K | ﹤0.01% | 1043 |
|
|
2014
Q4 | $1.37M | Sell |
61,257
-4,881
| -7% | -$92.5K | ﹤0.01% | 1148 |
|
|
2014
Q3 | $1.04M | Buy |
66,138
+3,174
| +5% | +$47.4K | ﹤0.01% | 1176 |
|
|
2014
Q2 | $934K | Buy |
62,964
+204
| +0.3% | +$2.88K | ﹤0.01% | 1231 |
|
|
2014
Q1 | $1.01M | Buy |
+62,760
| New | +$1.07M | ﹤0.01% | 1223 |
|
|
2013
Q4 | – | Sell |
-62,278
| Closed | -$705K | – | 1474 |
|
|
2013
Q3 | $705K | Buy |
62,278
+3,830
| +7% | +$52.6K | ﹤0.01% | 1299 |
|
|
2013
Q2 | $782K | Buy |
+58,448
| New | +$718K | ﹤0.01% | 1252 |
|
Other funds holding NBIX
VPM
VCM
American Century Companies's NBIX Position: Q1 2026 in Review
American Century Companies reduced its Neurocrine Biosciences (NBIX) stake by 5.2% in Q1 2026, selling an estimated $1.09M and leaving 150,298 shares worth $19.8M. The position accounts for 0.01% of the portfolio, ranked #1186.
American Century Companies first reported a position in NBIX in Q2 2013 and has held it in 50 quarters since. The position peaked at $114M in Q3 2023. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- American Century Companies held 150,298 shares of Neurocrine Biosciences worth $19.8M as of Q1 2026.
- American Century Companies sold 8,187 Neurocrine Biosciences shares in Q1 2026, an estimated $1.09M.
- Neurocrine Biosciences made up 0.01% of American Century Companies's portfolio in Q1 2026, its #1186 holding.
- American Century Companies first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 50 quarters since.
- American Century Companies's Neurocrine Biosciences position peaked at $114M in Q3 2023.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.